Core Viewpoint - The company announced that its joint venture, Yangzhou Shizhiyuan Biotechnology Co., Ltd., has recently been granted a patent by the National Intellectual Property Administration for an invention related to monoclonal antibodies targeting CD4, aimed at preventing, treating, and functionally curing HIV infections [1] Group 1 - The patent is specifically for a method involving monoclonal antibodies against CD4, their compositions, and the use of these compositions in the context of HIV infection [1] - This development represents a significant advancement in the treatment and potential functional cure for HIV, highlighting the company's innovative capabilities in biotechnology [1]